|Articles|December 9, 2021
- Pharmaceutical Executive-12-01-2021
- Volume 41
- Issue 12
Pharmaceutical Executive, December 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 5 years ago
New Bespoke Gene Therapy Consortium Is Welcome Developmentalmost 5 years ago
2022 Pipeline Report: Capitalizing on Opportunityalmost 5 years ago
Oncology Optimistalmost 5 years ago
What Does the Future Hold for Biopharma in 2022?almost 5 years ago
Playing the Long Game on Tighter Than Label Coveragealmost 5 years ago
Real-World Problems for Real-World Data Guidance?almost 5 years ago
Looking Back at Our Leadership Lessons From the Past Yearalmost 5 years ago
IP and Pharmaceutical Trade: Europe’s Unresolved Debatealmost 5 years ago
Pandemic Alters Policies and Practices for Drug DevelopmentAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
340B Under Pressure: Inside Pharma's Push for Greater Clarity
3
The Agentic AI Revolution in Biopharma
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5

